Supplemental Information

Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis

Yu-Shui Ma, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Xu-Chao Zhu, Ji-Bin Liu, Fei Yu, Zhi-Zhen Li, Jing-Han Wang, Qing-Xiang Gao, Bin Yi, Hui-Min Wang, Li-Peng Gu, Liu Li, Lin-Lin Tian, Yi Shi, Xiao-Qing Jiang, Da Fu, and Xiong-Wen Zhang
Supplemental Information

Long noncoding RNA OIP5-AS1 promotes the progression of liver hepatocellular carcinoma via regulating hsa-miR-26a-3p/EPHA2 axis

Supplemental information contains three supplemental figures and legends.
Supplementary Figure 1. Identification of significantly dysregulated lncRNAs in LIHC. (A) Hierarchical clustering of significantly dysregulated lncRNAs in LIHC was performed using the multiple experiment viewer 4.7.1 software programs. (B-D) The Kaplan-Meier method was used to evaluate the relationship between lncRNA CRNDE (B), OIP5-AS1 (C) and ZEB1-AS1 (D) expression and overall survival of 371 LIHC patients from TCGA datasets.
Supplementary Figure 2. The expression of OIP5-AS1 in LIHC samples.

(A-C) The expression level of CRNDE (A), OIP5-AS1 (B) and ZEB1-AS1 (C) in 371 LIHC tissues and 50 adjacent noncancerous tissues. (D-F) The correlation of CRNDE (D), OIP5-AS1 (E) and ZEB1-AS1 (F) in 371 LIHC tissues and 50 adjacent noncancerous tissues. (G) OIP5-AS1 expression level was examined in GSE104310 dataset. (H) OIP5-AS1 expression level was examined in GSE84005 dataset. (I) The correlation of OIP5-AS1 expression level and tumor stage in 371 LIHC patients.
Supplementary Figure 3. The expression and prognostic value of hsa-miR-26a-3p and in LIHC samples. (A) The expression level of hsa-miR-26a-3p in 371 LIHC tissues and 50 adjacent noncancerous tissues. (B, C) The expression level (B) and correlation (C) of hsa-miR-26a-3p in 50 pairs of LIHC tissues and adjacent noncancerous tissues. (D) The correlation of hsa-miR-26a-3p expression level and tumor stage in 371 LIHC patients. (E) The Kaplan-Meier method was used to evaluate the relationship between hsa-miR-26a-3p expression and overall survival of 371 LIHC patients. (F) The Kaplan-Meier method was used to evaluate the relationship between OIP5-AS1/hsa-miR-26a-3p expression and overall survival of 371 LIHC
patients. H/L, high OIP5-AS1 and low hsa-miR-26a-3p expression; L/H, low OIP5-AS1 and high hsa-miR-26a-3p expression. (G, H) The correlation between hsa-miR-26a-3p and OIP5-AS1 in 50 adjacent noncancerous tissues (H) and 371 LIHC tissues (G). (I) Hsa-miR-26a-3p expression level was examined in GSE21362 dataset. (J) Hsa-miR-26a-3p expression level was examined in GSE36915 dataset. (K) Hsa-miR-26a-3p expression level in 241 adjacent noncancerous tissues, 180 non-metastatic and 60 metastatic LIHC tissues from GSE6857 dataset. (L) Hsa-miR-26a-3p expression level in 178 alive and 59 dead LIHC patients from GSE6857 dataset.